The Tomosynthesis Mammographic Imaging Screening Trial (TMIST) is more than halfway to its recruiting goal of 128,905 participants, with more than 20% of participants in the United States being Black. Recruitment of women from diverse backgrounds is vital to ensuring that TMIST trial results will be applicable across races, ethnicities, and under-served communities.
FDA issued three final guidances to industry regarding cancer clinical trials that parallel the goals of President Biden’s recently announced effort to renew and build upon his 2016 Cancer Moonshot initiative to facilitate continued advancement in cancer prevention, detection, research, and patient care (The Cancer Letter, Feb. 4, 2022).
B.J. Rimel, associate professor of obstetrics and gynecology at Cedars-Sinai Cancer at the Cedars-Sinai Medical Center, has been named medical director for the Cancer Clinical Trials Office.
Marie Wood was named medical director of the Cancer Clinical Trials Office at The University of Colorado Cancer Center.
Since COVID-19 made its way to the United States, we have seen a stream of worrying news of the pandemic’s impact on cancer care in the U.S., including 9.4 million missed screenings for just about all forms of cancer. While screening rates rebounded in the fall of 2020, there’s a growing concern from oncologists that screenings haven’t returned to pre-pandemic levels for everyone.
Wells Messersmith has been named chief medical officer of oncology services at University of Colorado Health.
Sanjay Goel was named director of the Phase I/Investigational Therapeutics Program at Rutgers Cancer Institute of New Jersey.
Veru Inc. and Eli Lilly and Company entered into a clinical trial collaboration and supply agreement to evaluate the efficacy and safety of enobosarm, Veru’s first-in-class, selective androgen receptor targeting agonist, in combination with Lilly’s Verzenio (abemaciclib), a CDK4/6 inhibitor, as a second line therapy in the treatment of AR+ER+HER2- metastatic breast cancer.
NCI has issued a Request for Information seeking input from developers of multi-cancer early detection liquid biopsy tests, with the goal of launching an NCI-sponsored randomized controlled screening clinical trial of these tools.
Wendy Stock and Geoffrey Uy were named co-chairs of the Leukemia Committee of the Alliance for Clinical Trials in Oncology.
